<DOC>
	<DOCNO>NCT01663766</DOCNO>
	<brief_summary>This study ass safety tolerability milatuzumab ( IMMU-115 ) add standard regimen prevent Graft v . Host Disease ( GVHD ) patient hematologic malignancy undergo stem cell transplant .</brief_summary>
	<brief_title>Phase I Study Milatuzumab Graft Versus Host Disease</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Males nonpregnant , nonlactating female , ≥ 18 year age Able understand willing sign inform consent . Histologically confirm hematologic malignancy deem best treat RIC allogeneic SCT , include : Acute myeloid lymphoblastic leukemia ( AML , ALL ) &lt; 5 % blast bone marrow Myelodysplastic syndrome intermediate2 highrisk IPSS score &lt; 5 % blast bone marrow Chronic myelogenous leukemia fail respond least two different tyrosine kinase inhibitor Multiple myeloma relapse follow autologous stem cell transplant Follicular lymphoma ( grades 1 , 2 , 3a WHO criterion ) monocytoid lymphoma relapse follow least two prior chemotherapy regimens either lymph node group ≥ 3 cm ≥ 50 % reduction estimate lymph node diameter recent salvage therapy Diffuse large Bcell NHL relapse least 2 prior chemotherapy regimen ( could include highdose chemotherapy autologous stem cell rescue ) still sensitive chemotherapy virtue PR CR follow recent salvage chemotherapy Transformed follicular lymphoma achieve PR CR follow chemotherapy Mantle cell lymphoma relapse least 2 prior chemotherapy regimen ( could include highdose chemotherapy autologous stem cell rescue ) CLL/SLL/PLL meet one following : del ( 17p13.1 ) first remission Response good PR chemoimmunotherapy relapse within 2 year chemoimmunotherapy Richter 's transformation Complex karyotype At least 4 week beyond prior chemotherapy ( exclude steroid ) , antibody therapy , radiation , radioimmunoconjugate therapy , kinase inhibitor discontinue least one week prior start condition regimen . ECOG performance status ≤ 2 Life expectancy great 3 month Adequate organ function measure follow within seven day begin conditioning : AST ( SGOT ) ≤ 3.0 x institutional upper limit normal ( IULN ) Total bilirubin ≤ 1.5 xIULN unless due Gilbert 's disease Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 50 mL/min DLCO &gt; 40 % symptomatic pulmonary disease LVEF echocardiogram MUGA least 30 % Women child bear potential men must agree use contraception prior study entry duration study participation . Matched ( 8/8 ) relate match unrelated donor identify . Haploidentical umbilical cord graft allow . Donor willing donate peripheral blood stem cell meet institutional criterion stem cell donation . Prior allogeneic stem cell transplant Patients require myeloablative condition regimen Patients best serve bone marrow transplant eligible study restrict peripheral stem cell . No suitable donor identify Prior anaphylactic response Grade 4 infusion reaction milatuzumab Uncontrolled intercurrent illness include limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Patients active hepatitis B infection eligible . Patients history hepatitis B ( surface antigen core antibody positive ) must take lamivudine equivalent study therapy one year completion milatuzumab . LVEF &lt; 30 % Seropositivity HIV Hepatitis C Patients know CNS lymphoma exclude poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . Active secondary malignancy exception nonmelanomatous skin cancer low risk prostate cancer observation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>GVHD ( acute chronic )</keyword>
	<keyword>acute myeloid lymphoblastic leukemia ( AML ALL )</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>Chronic myelogenous leukemia ( CML )</keyword>
	<keyword>Multiple Myeloma ( MM )</keyword>
	<keyword>Non-Hodgekin lymphoma ( NHL-both follicular &amp; diffuse large cell )</keyword>
	<keyword>Chronic lymphocytic leukemia small lymphocytic leukemia ( CLL SLL )</keyword>
</DOC>